Gil Bashe
Chair Global Health and Purpose, FINN Partners, Editor-in-Chief, Medika Life, Galien Foundation Committee Liaison
Gil Bashe
Chair Global Health and Purpose, FINN Partners, Editor-in-Chief, Medika Life, Galien Foundation Committee Liaison
Daniella Kranjac
Founding GP, Avant Bio
Daniella Kranjac
Founding GP, Avant Bio
Product: Avant Bio Fund II LP
Company: Avant Bio
About the Product:
AVANT BIO is a growth equity firm focused on the enabling technologies shaping how tomorrow’s therapeutics are discovered, developed, and manufactured with an investment focus that accelerates new growth and innovation at various stages of company development. With a commitment to amplifying value and a forward-looking investment strategy, AVANT BIO is primed to unlock the full potential of therapeutic enabling technologies, TechBio, and Healthtech. For further information, including opportunities to partner, visit www.avant.bio. Follow AVANT BIO on LinkedIn for the latest news and industry insights.
Arnab Chatterjee
Vice President, Medicinal Chemistry, Calibr-Skaggs Institute for Innovative Medicines
Arnab Chatterjee
Vice President, Medicinal Chemistry, Calibr-Skaggs Institute for Innovative Medicines
Product: Calibr-Skaggs Drug Accelerator
Company: Calibr-Skaggs Institute for Innovative Medicines Decline
About the Product:
The Calibr-Skaggs Drug Development Accelerator at Scripps Research transforms bold science into life-changing therapies for patients worldwide. Our mission is to tackle urgent health challenges—from cancer and autoimmune disorders to infectious and neurodegenerative diseases—through pioneering platforms like switchable CAR-T and multivalent antibody therapeutics. By uniting cutting-edge discovery with translational expertise, we accelerate breakthrough medicines from lab to clinic, ensuring innovations reach those who need them most. Through global collaborations and a relentless focus on patient outcomes, we aim to redefine what’s possible in drug development and improve lives across every corner of the world.
Ying Yang
Director, Center for Life Science Ventures
Ying Yang
Director, Center for Life Science Ventures
Product: Center for Life Science Ventures
Company: Cornell University
About the Product:
Megane Dover
Junior Partner, Cross-Border Impact Ventures
Megane Dover
Junior Partner, Cross-Border Impact Ventures
Product: Women's and Children's Health Technology Fund
Company: Cross-Border Impact Ventures
About the Product:
Cross-Border Impact Ventures is an impact venture capital firm on a mission to revolutionize venture investing in health technology. Through the Women's and Children's Health Technology Fund, Cross-Border Impact Ventures invests in early-growth stage health technology companies commercializing medical devices, diagnostics, therapeutics, and digital health innovations and leveraging cutting-edge technologies like Artificial Intelligence (AI) and Machine Learning (ML). All innovations the Fund finances are relevant to women’s, children’s, and adolescents’ health and located in North America and Europe, with the ability to scale technologies to emerging markets. Cross-Border Impact Ventures is driven by the belief that good health should not be restricted by gender, age, race, wealth, or borders, and seeks to expand access to its portfolio’s world-class technologies inclusively and globally.
Christopher Hentschel
Chief Scientific Officer, Cube Labs
Christopher Hentschel
Chief Scientific Officer, Cube Labs
Product: Cube Labs
Company: Cube Labs
About the Product:
Cube Labs, Italy's leading venture builder in the healthcare technology space, bridges the gap between excellent local academic R&D and the global life sciences market. Evolving from its Italian origins, it has become a pan-European entity with a global reach. Cube Labs’ mission is to translate scientific research into impactful, real-world solutions while spearheading the democratization of life sciences for a healthier, more inclusive world where all individuals can benefit from innovation. Since its founding, Cube Labs has launched 15 startups and registered two products. In March 2023, it was listed on the Milan Stock Exchange, validating its vision and attracting growing interest in healthcare tech innovation.
Isaac Middelmann
Accelerator Director - Strategic Fundraising, EIT Health
Isaac Middelmann
Accelerator Director - Strategic Fundraising, EIT Health
Product: Venture Centre of Excellence (VCoE)
Company: EIT Health
About the Product:
The EIT Health Accelerator offers tip-to-tail pan-European support for innovative start-ups and SMEs across all life science and health subsectors to ensure that unmet patient and market needs are addressed at a truly global scale. Leveraging its 8+ year track record of supporting 2500+ start-ups, EIT Health Accelerator empowers fully tailored access to innovation for Corporates, VCs, payors and others, enabling collaboration with the best pan-European innovation. In so doing, the EIT Health Accelerator tackles critical global needs around healthcare innovation equity, both meeting present unmet needs and equipping the sector to resiliently face both known and unknown future challenges.
Deepak Hegde
Founder and Andrew Hamilton Director, Endless Frontier Labs - New York University Stern School of Business
Deepak Hegde
Founder and Andrew Hamilton Director, Endless Frontier Labs - New York University Stern School of Business
Product: Endless Frontier Labs
Company: Endless Frontier Labs - New York University Stern School of Business
About the Product:
Endless Frontier Labs (EFL) is a global accelerator program based at NYU Stern that empowers early-stage science and technology startups to turn breakthrough research into scalable, high-impact ventures. EFL provides founders with tailored mentorship, strategic guidance, and access to a vast network of investors, industry experts, and corporate partners. The program focuses on helping startups navigate critical early-stage challenges from product development and regulatory strategy to fundraising and commercialization. By combining rigorous scientific insight with entrepreneurial support, EFL accelerates the path from innovation to market, fostering startups that can tackle pressing global challenges in areas such as life sciences, energy, and advanced technology.
Barbara Marusiak
Director, MedTech Accelerator
Barbara Marusiak
Director, MedTech Accelerator
Product: Mayo Clinic and ASU Alliance for Health Care Accelerator
Company: Mayo Foundation for Medical Education and Research
About the Product:
Where Innovation Meets Impact in Health Care. The Mayo Clinic and ASU Alliance for Health Care Accelerator is a pioneering collaboration that unites the clinical excellence of Mayo Clinic with the innovation ecosystem of Arizona State University. Designed to accelerate breakthroughs in healthcare products, services and solutions, the program offers unparalleled access to clinical validation, expert mentorship, and a robust commercialization pathway. Startups benefit from direct engagement with world-renowned clinicians, regulatory experts, and venture capital networks. This accelerator transforms visionary ideas into life-saving solutions, empowering healthcare innovators to scale with purpose and precision. This one-of-a-kind collaboration exemplifies the power of interdisciplinary partnership to advance medical science and improve lives.
Kika Armata
Associate Director, McGill Dobson Centre for Entrepreneurship
Kika Armata
Associate Director, McGill Dobson Centre for Entrepreneurship
Product: McGill Dobson Centre for Entrepreneurship
Company: McGill Dobson Centre for Entrepreneurship
About the Product:
The McGill Dobson Centre for Entrepreneurship hub of entrepreneurship at McGill University with the mission to teach, coach, and support entrepreneurs stemming from McGill’s 11 faculties, 13 schools, and 35 research centers as they seek to build innovative companies with a purpose. With 14 learning pathways spanning four stages of the entrepreneurial journey and customized to different sectors, the Dobson Centre proudly stands as a global leader in entrepreneurship, committed to catalyzing sustainable socio-economic impact both locally and globally while addressing all 17 UN Sustainable Development Goals. With thousands of ventures supported, we count over 530 active startups who cumulatively raised $4.1 billion, own 258 active patents, created 12,000 jobs, operate in 48 countries, and collaborate with 123 universities.
Oliver Dodd
Executive Director, Nucleate Bio, Inc.
Oliver Dodd
Executive Director, Nucleate Bio, Inc.
Product: The Activator
Company: Nucleate
About the Product:
The Activator is a new model to support founders without charging fees or taking equity - empowering academic scientists to launch biotech ventures that address challenges in human and planetary health. Through our grassroots approach, we source technologies from 400+ academic institutions across 40 global chapters. Volunteer PhDs evaluate innovations for real-world impact, then match scientific founders with co-founders to build well-rounded teams. With mentorship from 2,000+ industry leaders, a structured curriculum on IP, regulatory, and fundraising, and direct investor connections, the Activator has already supported 610 technologies, launched 183 companies, raised $570M, and created 800+ jobs - real innovation, real outcomes.